NCT05360277View on ClinicalTrials.gov

Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

August 22, 2023

Primary Completion Date

February 28, 2025

Study Completion Date

November 30, 2027

Conditions
Metastatic Colorectal Cancer，NED
Interventions
DRUG

Tislelizumab + Capecitabine

"Tislelizumab 200mg iv every 3 weeks, for 1 year after completion of perioperative chemotherapy.~Capecitabine was given at a dose of 850 mg/m2 twice a day by mouth, 2 weeks on/ 1 week off, for 1 year after completion of perioperative chemotherapy."

OTHER

Best supportive care

Best supportive care

Trial Locations (1)

510655

RECRUITING

Gastrointestinal Hospital, Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Yanhong Deng

OTHER